AbbVie competitorsClear all
AbbVie's top competitors include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
| Save Comparison |  AbbVie AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. |  Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases. |  Abbott Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines. |  Novartis Novartis is a company that researches, develops, manufactures, and markets a range of healthcare products. |  Roche Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. |  Johnson & Johnson Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. | |||
Founding Date | Founding Date 2013 | Founding Date 1987 | Founding Date 1982 | Founding Date 2004 | Founding Date 1980 | Founding Date 1887 | Founding Date 1888 | Founding Date 1668 | Founding Date 2000 | Founding Date 1996 | Founding Date 1896 | Founding Date 1886 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Foster City, US HQ Abb, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Morris Plains, US HQ Rödermark, DE | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Kew, AU North Ryde, AU Wien, AT Machelen, BE see more | Locations New York, US HQ Braine L'alleud, BE Watermaal Bosvoorde, BE Montréal, CA Pudong Xinqu, CN Virum, DK Espoo, FI see more | Locations Lake Bluff, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Brentford, GB HQ Tirane, AL Boudouaou, DZ Victoria, AR Abbotsford, AU Boronia, AU Wien, AT see more | Locations Basel, CH HQ Hydra, DZ Ricardo Rojas, AR Bella Vista, AU North Ryde, AU Sydney, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Yerevan, AM Ultimo, AU Wien, AT Minsk, BY Beerse, BE see more | ||||
Employees | Employees 30,000 | Employees 11,8007% increase | Employees 3666% increase | Employees 100,4094% decrease | Employees 23,4009% increase | Employees 30,00029% increase | Employees 107,0004% increase | Employees 57,0719% increase | Employees 99,4374% increase | Employees 103,91417% decrease | Employees 97,7353% increase | Employees 132,2002% decrease |
Valuation ($) | Valuation ($) 152.2 b | Valuation ($) 78 b | Valuation ($) 19.7 b | Valuation ($) 126.4 b | Valuation ($) 142.8 b | Valuation ($) 134.1 b | Valuation ($) 183.2 b | Valuation ($) 62 b | Valuation ($) 94 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 383.5 b |
Twitter followers | Twitter followers 65.4 k | Twitter followers 63.7 k | Twitter followers 616 | Twitter followers 132.1 k | Twitter followers 92.7 k | Twitter followers 144.8 k | Twitter followers 103.9 k | Twitter followers 19.1 k | Twitter followers 204.4 k | Twitter followers 273.9 k | Twitter followers 219.7 k | Twitter followers 203.9 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 53 | Number of tweets (last 30 days) 25 | Number of tweets (last 30 days) 10 | Number of tweets (last 30 days) 69 | Number of tweets (last 30 days) 87 | Number of tweets (last 30 days) 89 | Number of tweets (last 30 days) 165 | Number of tweets (last 30 days) 69 | Number of tweets (last 30 days) 68 | Number of tweets (last 30 days) 17 | Number of tweets (last 30 days) 103 | Number of tweets (last 30 days) 52 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 7 | Average likes per tweet (last 30 days) 25.4 | Average likes per tweet (last 30 days) 9.6 | Average likes per tweet (last 30 days) 44.9 | Average likes per tweet (last 30 days) 19 | Average likes per tweet (last 30 days) 10.2 | Average likes per tweet (last 30 days) 9.3 | Average likes per tweet (last 30 days) 3.1 | Average likes per tweet (last 30 days) 21.5 | Average likes per tweet (last 30 days) 4.9 | Average likes per tweet (last 30 days) 15.3 | Average likes per tweet (last 30 days) 35.8 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 90.57% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 97.7% | Percentage of tweets with engagement (last 30 days) 98.88% | Percentage of tweets with engagement (last 30 days) 53.94% | Percentage of tweets with engagement (last 30 days) 86.96% | Percentage of tweets with engagement (last 30 days) 76.47% | Percentage of tweets with engagement (last 30 days) 35.29% | Percentage of tweets with engagement (last 30 days) 97.09% | Percentage of tweets with engagement (last 30 days) 86.54% |
Alexa Website Rank | Alexa Website Rank 103395 | Alexa Website Rank 132640 | Alexa Website Rank 297616 | Alexa Website Rank 183341 | Alexa Website Rank 185690 | Alexa Website Rank 97151 | Alexa Website Rank 37982 | Alexa Website Rank 99354 | Alexa Website Rank 35293 | Alexa Website Rank 101380 | Alexa Website Rank 65019 | Alexa Website Rank 24994 |
Employee Rating | Employee Rating 3.9 | Employee Rating 3.5 | Employee Rating 2.8 | Employee Rating 3.3 | Employee Rating 3.8 | Employee Rating 4 | Employee Rating 3.6 | Employee Rating 4 | Employee Rating 3.9 | Employee Rating 4 | Employee Rating N/A | Employee Rating 4.1 |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $33.3b (FY, 2019) | Revenue (est.) $22.4b (FY, 2019) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) €37.1b (FY, 2015) | Revenue (est.) $23.4b (FY, 2019) | Revenue (est.) $26.1b (FY, 2019) | Revenue (est.) $31.9b (FY, 2019) | Revenue (est.) €14.8b (FY, 2018) | Revenue (est.) £33.8b (FY, 2019) | Revenue (est.) $47.4b (FY, 2019) | Revenue (est.) CHF63.8b (FY, 2019) | Revenue (est.) $82.1b (FY, 2019) |
Cost of goods | Cost of goods $7.4b (FY, 2019) | Cost of goods $4.7b (FY, 2019) | Cost of goods N/A | Cost of goods €10.9b (FY, 2015) | Cost of goods $4.4b (FY, 2019) | Cost of goods $8.1b (FY, 2019) | Cost of goods $13.2b (FY, 2019) | Cost of goods €5.4b (FY, 2018) | Cost of goods £11.9b (FY, 2019) | Cost of goods $13.2b (FY, 2019) | Cost of goods CHF18.4b (FY, 2019) | Cost of goods $27.6b (FY, 2019) |
Gross profit | Gross profit $25.8b (FY, 2019) | Gross profit $17.8b (FY, 2019) | Gross profit $295k (FY, 2019) | Gross profit €26.1b (FY, 2015) | Gross profit $19b (FY, 2019) | Gross profit $18.1b (FY, 2019) | Gross profit $18.7b (FY, 2019) | Gross profit €9.5b (FY, 2018) | Gross profit £21.9b (FY, 2019) | Gross profit $34.2b (FY, 2019) | Gross profit CHF45.4b (FY, 2019) | Gross profit $54.5b (FY, 2019) |
Net income | Net income $7.9b (FY, 2019) | Net income $5.4b (FY, 2019) | Net income ($357.3m) (FY, 2019) | Net income €4.4b (FY, 2015) | Net income $7.8b (FY, 2019) | Net income $3.5b (FY, 2019) | Net income $3.7b (FY, 2019) | Net income €3.4b (FY, 2018) | Net income £5.3b (FY, 2019) | Net income $11.7b (FY, 2019) | Net income CHF14.1b (FY, 2019) | Net income $15.1b (FY, 2019) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries 35 (FY, 2019) | Countries N/A | Countries N/A | Countries 100 (FY, 2019) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 60 (FY, 2018) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 7 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 87 (FY, 2016) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 97 (FY, 2019) |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 92 (FY, 2019) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 23 (FY, 2019) | Manufacturing Sites N/A |
New Product Launches | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches 25 (FY, 2018) | New Product Launches N/A | New Product Launches 30 (FY, 2016) | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A |
Partners | Partners 220 (FY, 2018) | Partners N/A | Partners N/A | Partners N/A | Partners N/A | Partners N/A | Partners N/A | Partners N/A | Partners 2 k (FY, 2017) | Partners N/A | Partners N/A | Partners N/A |
Patent Applications (US) | Patent Applications (US) N/A | Patent Applications (US) 393 (Sep, 2020) | Patent Applications (US) 275 (Sep, 2020) | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A |
Patents (US) | Patents (US) N/A | Patents (US) 642 (Sep, 2020) | Patents (US) 390 (Sep, 2020) | Patents (US) N/A | Patents (US) 34 (FY, 2019) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Patients | Patients 30 m (FY, 2018) | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients 63.2 m (FY, 2019) | Patients N/A |
Patients Included in Clinical Trials | Patients Included in Clinical Trials 104 k (FY, 2018) | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials 282.5 k (FY, 2019) | Patients Included in Clinical Trials N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products 22 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2019) | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2019) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 4 (FY, 2019) | Phase III Trials Products 7 (Y, 2016) | Phase III Trials Products 14 (Feb, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 38 (FY, 2019) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 9 (FY, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 20 (FY, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products 24 (FY, 2019) | Products N/A | Products N/A | Products N/A | Products N/A | Products 1.5 k (FY, 2019) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 43 (Y, 2016) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 44 (FY, 2016) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 12 (FY, 2019) | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 29 (FY, 2019) | Research and Development Centers N/A |
Suppliers | Suppliers 51 k (FY, 2018) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 3.5 k (Jun, 2018) |
US FDA Breakthrough Therapy Designations | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations 6 (FY, 2017) | US FDA Breakthrough Therapy Designations 4 (FY, 2019) | US FDA Breakthrough Therapy Designations N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 30m | Total funding raised $ 310m | Total funding raised $ 175.5m | Total funding raised $ 15.5m | Total funding raised $ 6.9m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 2.8b | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
Gilead Sciences
HQ
Foster City, US
Employees
11,800↑ 7% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
View companyImmunomedics
HQ
Morris Plains, US
Employees
366↑ 6% increase
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View company
Sanofi
HQ
Paris, FR
Employees
100,409↓ 4% decrease
Sanofi is a company providing healthcare solutions.
View companyAmgen
HQ
Thousand Oaks, US
Employees
23,400↑ 9% increase
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
View company